In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
An antibody-drug conjugate (ADC) from AstraZeneca and Daiichi Sankyo has secured approval in China. 24 February 2023
Biotechnology
At its February meeting, the European Medicines Agency’s human medicines committee CHMP recommended approval of eight novel medicines, one of which is a biosimilar. 24 February 2023
Biotechnology
The US Food and Drug Administration (FDA) has approved Altuviiio (efanesoctocog alfa), a high-sustained factor VIII replacement therapy. 24 February 2023
Pharmaceutical
Germany’s Merck KGaA has announced updated long-term efficacy and safety data for its investigational small molecule evobrutinib. 24 February 2023
Biotechnology
Shares of Nektar Therapeutics sank more than 40% to $1.78 in pre-market activity today after the company reported that a study of rezpegaldesleukin (rezpeg) did not achieve its goals and that partner Eli Lilly has decided not to proceed with Phase III development of the investigational treatment for systemic lupus erythematosus (SLE). 24 February 2023
Pharmaceutical
US precision oncology company Enliven Therapeutics today announced that, concurrent with the completion of its previously announced merger with Imara, it has completed a $165 million private placement. 24 February 2023
Biotechnology
Two and half years after the Swiss pharma giant paid $775 million up front to in-license the RET inhibitor, as part of a $1.7 billion deal with US biotech Blueprint Medicines, Roche is pulling out of the deal to develop Gavreto (pralsetinib), citing “strategic reasons”. 24 February 2023
Biotechnology
Pfizer has already reported eye-watering annual revenue of $100.3 billion for 2022 driven by its products related to the COVID-19 pandemic, notably the Comirnaty vaccine, which witnessed a record demand last year with forecast sales of $37 billion. 24 February 2023
Biotechnology
California, USA-based precision medicine company Cartography Biosciences, which launched in July last year with $57 million financing, has appointed Chester Wong as vice president, head of business development. 24 February 2023
Pharmaceutical
An Expert View from David Bleakman, president, Drug Discovery and Development at PsychoGenics. 24 February 2023
Biotechnology
US pharma major AbbVie and privately-held gene therapy company Capsida Biotherapeutics have expanded their strategic collaboration on the development of genetic medicines for eye diseases with high unmet need. 23 February 2023
Biotechnology
Today, Dutch gene therapy company uniQure announced that the prestigious New England Journal of Medicine (NEJM) has published data from the pivotal Phase III HOPE-B study evaluating the efficacy, durability and safety of Hemgenix (etranacogene dezaparvovec-drlb), the first gene therapy approved for the treatment of adults with hemophilia B. 23 February 2023
Biotechnology
US mRNA specialist biotech Moderna today reported financial results for the fourth quarter and fiscal year 2022 that disappointed and sent its shares down 7.5% at $146.63 in mid-morning in trading. 23 February 2023
Biotechnology
UK pharma major AstraZeneca (LSE: AZN) saw its shares dip 1.2% after it announced an exclusive global license deal with KYM Biosciences. 23 February 2023
Biotechnology
Struggling to finance further development of its immunotherapy candidates alone, Jounce Therapeutics has announced plans to merge with British firm Redx Pharma. 23 February 2023
Biotechnology
Two more American biotech companies have been forced to announce plans to restructure, including mandatory redundancies, to avoid looming financial trouble. 23 February 2023
Pharmaceutical
HIV specialist company ViiV Healthcare has announced positive 12-month findings from the SOLAR study. 23 February 2023
Biotechnology
Rare Disease Day is honored globally on February 28 each year. For a long time, the number of known rare diseases in the world was pegged between 6,000 and 8,000. 23 February 2023
Biotechnology
French clinical-stage biotech Abivax yesterday announced the successful pricing of an oversubscribed 130 million-euro ($139 million) financing with high-quality US and European biotech specialist investors, adding to the 49 million-euro fundraising in September last year. 23 February 2023
Generics
Four applicants have received the first tranche of incentives under India's Production Linked Incentive (PLI) scheme released by the Department of Pharmaceuticals (DoP), which awarded the Indian drugmakers $20 million. 23 February 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze